Plasma metabolomic signatures of breast cancer

Frontiers in Medicine

Medicine

Bin Zhao¹  Zhu Xu²  Yali Xu³  Qiang Sun³  Xiaogang Li⁴ 

[1]Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

[2]Department of Gastrointestinal Surgery II, Renmin Hospital of Wuhan University, Wuhan, Hubei, China

[3]State Key Laboratory of Complex Severe and Rare Diseases, Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

[4]State Key Laboratory of Complex Severe and Rare Diseases, Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

关键词: breast cancer;    breast benign abnormalities;    metabolomics;    lipidomics;    biomarker;   

DOI  :  10.3389/fmed.2023.1148542

 received in 2023-01-20, accepted in 2023-07-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundBreast cancer is a common malignant tumor. A large number of medical evidence shows that breast cancer screening can improve the early diagnosis rate and reduce the mortality rate of breast cancer. In the present study, a wide range of targeted metabolomics profiling was conducted to investigate the plasma signatures of breast cancer.MethodsA total of 86 patients with benign breast abnormalities (L group) and 143 patients with breast cancer (E group) were recruited. We collected their plasma samples and clinical information. Metabolomic analysis, based on the coverage of a wide range of targeted metabolomics was conducted with ultraperformance liquid chromatography- triple quadrupole-linear ion trap mass spectrometer (UPLC-QTRAP-MS).ResultsWe identified 716 metabolites through widely-targeted metabolomics. Serotonergic synapse was the main different metabolic pathway. The fold change of 14 metabolites was considered significantly different (fold change <0.67 or fold change >2; p < 0.05). By combining all the 14 metabolites, we achieved differentiation of L group vs. E group (AUC = 0.792, 95%Cl: 0.662–0.809).ConclusionThis study provided new insights into plasma biomarkers for differential diagnosis of benign abnormalities and breast cancer.

【 授权许可】

Unknown   
Copyright © Xu, Zhao, Xu, Li and Sun.